Halozyme Therapeutics | HALO - Cash And Equivalent


Halozyme Therapeutics reported $133.82M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Cara Therapeutics USD 20.65M 13.57M Jun/2025
Cytokinetics USD 122.52M 102.95M Dec/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
MannKind USD 74.88M 52.51M Dec/2025
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
United Therapeutics USD 1.56B 217M Dec/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025